account5 million) in the first quarter from 9 million in the fourth quarter. The drug is sold by GlaxoSmithKline (GSK.L: Quote, Profile, Research). Genmab said the guidance for 2011 includes no drug development milestone payments from GSK. "We anticipate that...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Genmab keeps 2011 guidance after Q1 losses narrow
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account